Sugi Predict

Sugi Predict / Compounds / SCHEMBL1474216

SCHEMBL1474216

SCHEMBL1474216

CC(C)(c1ccc(C2CC2C(=O)O)cc1)C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 9/20 0.50
▸ EPHX2 P34913 1/20 0.46
▸ IDO1 P14902 1/20 0.40
▸ RORC P51449 2/20 0.40
▸ HRH3 Q9Y5N1 1/20 0.40
▸ P2RY14 Q15391 2/20 0.39
▸ TMEM97 Q5BJF2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ CNR1 P21554 1/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ TRPV1 Q8NER1 1/20 0.38
▸ HDAC4 P56524 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1474207 0.83 FFAR1 (0.55) FFAR1EPHX2HRH3ALDH1A1CYP1A2
SCHEMBL1474653 0.83 FFAR1 (0.54) FFAR1EPHX2IDO1P2RY14TMEM97
SCHEMBL1474431 0.83 FFAR1 (0.54) FFAR1EPHX2IDO1P2RY14TMEM97
SCHEMBL301271 0.83 FFAR1 (0.55) FFAR1EPHX2HRH3ALDH1A1CYP1A2
SCHEMBL1795393 0.83 FFAR1 (0.54) FFAR1EPHX2IDO1P2RY14TMEM97
SCHEMBL23425321 0.83 FFAR1 (0.54) FFAR1EPHX2IDO1P2RY14TMEM97
SCHEMBL10288267 0.83 FFAR1 (0.55) FFAR1EPHX2HRH3ALDH1A1CYP1A2
SCHEMBL1799765 0.83 FFAR1 (0.54) FFAR1EPHX2IDO1P2RY14TMEM97
SCHEMBL1473143 0.80 MAPT (0.41) ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL1475701 0.76 FFAR1 (0.38) FFAR1EPHX2IDO1HRH3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1861359-B1 N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN PFIZER (US) 2012-11-14 — — EP disclosed
US-20110152326-A1 SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS HANAZAWA TAKESHI 2011-06-23 — — US disclosed
US-7915448-B2 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER INC. (US) 2011-03-29 — — US disclosed
US-20100035880-A1 SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS PFIZER INC 2010-02-11 — — US disclosed
US-7622589-B2 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER INC. (US) 2009-11-24 — — US disclosed
EP-1866278-A1 SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS Pfizer, Inc. (US) 2007-12-19 — — EP disclosed
WO-2006103503-A1 SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS PFIZER JAPAN INC. (JP) 2006-10-05 — — WO disclosed
US-20060211741-A1 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER, INC. 2006-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211741-A1 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists CNR1, HVCN1, CNR2 FFAR1 21/4885EPHX2 3100/4885IDO1 1884/4885
US-20110152326-A1 SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS OPRL1, CNR1, TRPV1 FFAR1 91/4885EPHX2 1371/4885IDO1 1150/4885
US-20100035880-A1 SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS CNR1, HVCN1, CNR2 FFAR1 21/4885EPHX2 3139/4885IDO1 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.